Multidisciplinary Approach to Reduce Injury and Substance Abuse

Overview

The primary purpose of the project entitled: Multidisciplinary Approach to Reduce Injury and Substance Abuse, which is funded by the National Institute on Drug Abuse (5R01DA026088-02), is to compare the effectiveness of brief intervention, brief intervention plus a booster, and brief advice for adult patients who abuse drugs and present to a trauma department for treatment of an injury.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: April 2014

Detailed Description

Multidisciplinary Approach to Reduce Injury and Substance Abuse is a randomized clinical trial evaluating the effectiveness of brief advice (BA), brief motivational intervention with feedback (BMI), and brief motivational intervention with feedback and booster (BMI+B) in injured patients with drug problems. The setting is a level 1 Trauma Department, which serves a large and diverse patient population. Injured patients are screened for eligibility in the project based on a positive toxicology screen or self reported drug use in the past 90 days. The primary outcome of interest will be patients' subsequent drug use. Other outcomes of interest include: HIV-related risk behaviors, improved health outcomes (including injury reduction), increased employment, decreased engagement in illegal behavior, increased substance abuse treatment utilization, and enhanced quality of life at three, six, and twelve month follow-ups. This study will also examine the potential moderating and mediating effects of patient readiness to change, use of experiential and behavioral processes of change and decisional balance considerations. In addition, this project will examine implementation factors at the organizational level and the cost effectiveness of BA, BMI, and BMI+B. Study participants and their related identifying information will be collected during the time they are admitted to the recruitment hospital trauma department. Study participants must be 18 years or older, speak English or Spanish, have been admitted to the recruitment hospital trauma department, and test positive for illegal drugs or admit to illegal drug use when verbally screened. Additional information will be collected from participants in the in-person assessment interviews at three, six, and 12 month follow-up periods.

Interventions

  • Behavioral: Brief advice
    • The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
  • Behavioral: Brief Intervention plus Booster
    • A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
  • Behavioral: Brief Intervention
    • A brief drug use intervention based on motivational interviewing is provided to participants at baseline

Arms, Groups and Cohorts

  • Experimental: Brief Intervention
    • 30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk.
  • Active Comparator: Brief advice
    • This condition of the experiment acts a control and will be a short session in which the therapist will provide brief advice about drug use and give the patient a pamphlet.
  • Experimental: Brief Intervention plus Booster
    • 30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk plus a brief phone booster session at 1 month post-intake to review feedback, 2) assess progress, 2) renew motivation to change, and 3) evaluate and affirm commitment to change.

Clinical Trial Outcome Measures

Primary Measures

  • The primary outcome of interest will be patients’ subsequent drug use.
    • Time Frame: 3, 6, and 12 months after intervention

Secondary Measures

  • HIV risk-behaviors, improved health, increased employment, decreased illegal behavior, increased substance treatment, enhanced quality of life, use of Transtheoretical model of change, organization implementation, and intervention cost-effectiveness.
    • Time Frame: 3, 6, and 12 months after intervention

Participating in This Clinical Trial

Inclusion Criteria

  • Study participants must be 18 years or older – Speak English or Spanish – Been admitted to the level 1 Trauma Department – Test positive for illegal drugs or admit to illegal drug use Exclusion Criteria:
  • Other penetrating trauma not related to motor vehicle collisions, violence or falls, such as poisoning and, bites – Patients with traumatic brain injury, or a Glasgow Coma Scale score of less than 15 – Patients who do not pass the Mini-Mental Status Exam are excluded
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • University of Texas at Austin
    • Collaborator
      • National Institute on Drug Abuse (NIDA)
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • Mary M Velasquez, PhD, Principal Investigator, University of Texas at Austin
      • Craig A Field, PhD, Principal Investigator, University of Texas, El Paso

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.